TY  - JOUR
PB  - NATURE PORTFOLIO
ID  - discovery10203702
N2  - Myositis-specific autoantibodies (MSAs) have become pivotal biomarkers for idiopathic inflammatory myopathies and have revolutionized understanding of the heterogeneous disease spectrum that affects both adults and children. The discovery and characterization of MSAs have substantially enhanced patient stratification based on clinical phenotype, thereby facilitating more precise diagnosis and ultimately improving management strategies. Advances in immunoassay technologies in the past 20 years have further propelled the field forward, enabling the detection of a growing repertoire of autoantibodies with high specificity and sensitivity; however, evolving research over the past decade has revealed that even within antibody-defined subsets, considerable clinical diversity exists, suggesting a broader spectrum of disease manifestations than previously acknowledged. Challenges persist, particularly among patients who are seronegative, where the failure to identify certain rare MSAs stems from the use of diverse detection methodologies and inadequate consensus-guided standardization and validation protocols. Bridging these diagnostic gaps is crucial for optimizing patient care and refining prognostic stratification in idiopathic inflammatory myopathies.
KW  - Science & Technology
KW  -  Life Sciences & Biomedicine
KW  -  Rheumatology
KW  -  INTERSTITIAL LUNG-DISEASE
KW  -  MYOSITIS-SPECIFIC AUTOANTIBODIES
KW  -  NEUTROPHIL EXTRACELLULAR TRAPS
KW  -  SIGNAL RECOGNITION PARTICLE
KW  -  CYTOSOLIC 5'-NUCLEOTIDASE 1A
KW  -  CONNECTIVE-TISSUE DISEASE
KW  -  TRANSFER-RNA-SYNTHETASE
KW  -  GENE 5
KW  -  CLINICAL-SIGNIFICANCE
KW  -  SYSTEMIC-SCLEROSIS
EP  - 62
AV  - public
Y1  - 2025/01//
TI  - An update on autoantibodies in the idiopathic inflammatory myopathies
SN  - 1759-4790
UR  - https://doi.org/10.1038/s41584-024-01188-4
A1  - Allameen, NA
A1  - Ramos-Lisbona, AI
A1  - Wedderburn, LR
A1  - Lundberg, IE
A1  - Isenberg, DA
JF  - Nature Reviews Rheumatology
SP  - 46
VL  - 21
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
IS  - 1
ER  -